1. Anterior Gradient 2 is Correlated with EGFR Mutation in Lung Adenocarcinoma Tissues
- Author
-
Mikiyoshi Saito, Masahito Ebina, Erina Iwabuchi, Hironobu Sasano, Shuko Hata, Kazushige Mori, Sodai Narumi, Takashi Kondo, Yasuhiro Miki, Makoto Kobayashi, Hisafumi Yamada-Okabe, Chiaki Endo, Makoto Maemondo, Takashi Suzuki, Akira Inoue, Ikuro Sato, and Masakazu Ichinose
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Clinical Biochemistry ,Adenocarcinoma of Lung ,Adenocarcinoma ,Gene mutation ,Transfection ,medicine.disease_cause ,Disease-Free Survival ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Growth factor receptor ,Cell Line, Tumor ,medicine ,Humans ,Epidermal growth factor receptor ,Protein Kinase Inhibitors ,Mutation ,Lung ,biology ,Kinase ,Prognosis ,medicine.disease ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Immunohistochemistry ,Female - Abstract
Background Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) has demonstrated a promising therapeutic response in lung adenocarcinoma patients with EGFR gene mutations. However, the predictive factors for this therapy have not been established, except for the EGFR gene mutation status of carcinoma cells. Methods We first performed microarray analysis in EGFR-TKI–sensitive lung adenocarcinoma cell lines. The results indicated anterior gradient 2 (AGR2) as a potential surrogate marker of EGFR-TKI. Therefore, we then evaluated the correlation between the status of AGR2 immunoreactivity and clinicopathological factors including overall survival (OS), progression-free survival (PFS) and clinical response to EGFR-TKI, in 147 cases of surgically resected lung adenocarcinoma. The biological significance of AGR2 was further evaluated by transfecting small interfering RNA (siRNA) against AGR2 in these cells. Results The status of AGR2 immunoreactivity was significantly higher in lung adenocarcinoma cases with EGFR gene mutations than in those with the wild type (pConclusions AGR2 could serve as an adjunctive surrogate protein marker possibly reflecting EGFR gene mutations in lung adenocarcinoma patients. Results from in vitro analysis indicated that AGR2 could be a potential clinical biomarker of EGFR-TKI therapeutic sensitivity in lung adenocarcinoma cells.
- Published
- 2015